Dianthus Therapeutics Announces Positive Phase 2 Claseprubart Data in Myasthenia Gravis
Reuters
Oct 30, 2025
Dianthus <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Positive Phase 2 Claseprubart Data in Myasthenia Gravis
Dianthus Therapeutics Inc. has announced new data from its Phase 2 MaGic trial evaluating claseprubart in patients with generalized Myasthenia Gravis (gMG). The results, including new open-label extension data, were presented during the Myasthenia Gravis Foundation of America (MGFA) Scientific Session at the 2025 American Association of Neuromuscular and Electromagnetic Medicine (AANEM) Annual Meeting. The company highlighted the potential of 300mg/2mL Q4W dosing of claseprubart and plans to initiate a Phase 3 trial in 2026. The upcoming Phase 3 study will include two claseprubart treatment arms (300mg/2mL Q2W and 300mg/2mL Q4W) versus placebo, with a QMG ≥10 screening criterion. Dianthus also presented preclinical in vitro data suggesting efficacy benefits of upstream (active C1s) inhibition with claseprubart compared to downstream (C5) inhibition. Further details and a replay of the virtual industry forum are available on the company's website.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dianthus Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9564746-en) on October 29, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.